About
Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Team (17)
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
2
As Collaborator
3
Total Enrollment
205
By Phase
PHASE2: 2PHASE1: 3
By Status
RECRUITING: 2NOT_YET_RECRUITING: 1COMPLETED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07172256Collaborator
CUE-101with Pembrolizumab for LA-HPV+HNSCCs
PHASE2Not yet recruiting
30 participants
Started: Nov 30, 2025 · Completed: Nov 30, 2030
NCT06917885Collaborator
CUE-102 in Recurrent Glioblastoma
PHASE1Recruiting
18 participants
Started: Jul 30, 2025 · Completed: Jan 31, 2027
NCT05360680Lead Sponsor
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
PHASE1Completed
42 participants
Started: Jun 14, 2022 · Completed: Mar 12, 2025
NCT04852328Collaborator
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
PHASE2Recruiting
30 participants
Started: Dec 6, 2021 · Completed: Oct 31, 2027
NCT03978689Lead Sponsor
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
PHASE1Active, not recruiting
85 participants
Started: Jul 30, 2019 · Completed: Jan 31, 2026
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...